The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.
Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...
Please provide your email address to receive an email when new articles are posted on . Vadadustat is noninferior to darbepoetin alfa in preserving hemoglobin levels in patients with ...
DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...
Please provide your email address to receive an email when new articles are posted on . Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients ...
Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients Background: Anemia occurring in cancer patients undergoing Chemotherapy and or Radiotherapy causes ...
Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 Darbepoetin alfa (300 μg) or placebo was ...
STOCKHOLM—Whether darbepoetin alfa (DA) is administered in the middle or at the end of a hemodialysis session has no significant effect on hemoglobin levels, according to a French study. Some in vitro ...
According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective treatment for ...
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint. Vadadustat has met its primary and ...
Hosted on MSN
New study on darbepoetin shows how to best reduce need for blood transfusions in premature babies
A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results